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Neuroendocrine neoplasms (NENs) arise from the diffuse
neuroendocrine cell system and may occur at many
different disease sites. Most frequently, these neoplasms
occur in the digestive system, followed by the lung. The
term NEN encompasses well-differentiated neuroendocrine
tumours (NETs) and poorly differentiated neuroendocrine
carcinomas (NECs). NECs represent only 10%e20% of all
NENs. The main focus of these guidelines is on sporadic
small intestinal (SI)-NENs and pancreatic NENs (Pan-NENs)
since these are the most prevalent NENs at advanced
disease stages. In general, the management of other
gastrointestinal NENs follows the same principles as in SI- or
Pan-NENs taking into consideration key features of NENs
such as proliferative activity, somatostatin receptor (SSTR)
expression, tumour growth rate and extent of the disease.
Recommendation Diagnostic and therapeutic decision making should be
based on key features of NENs such as proliferative activ-
ity, SSTR expression, tumour growth rate and extent of
the disease [IV, A].
INCIDENCE AND EPIDEMIOLOGY
Gastroenteropancreatic NENs (GEP-NENs) constitute a
heterogeneous group of malignancies with a neuronalorrespondence to: ESMO Guidelines Committee, ESMO Head Office, Via
vra 4, CH-6900 Lugano, Switzerland.
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me xxx - Issue xxx - 2020phenotype and the capacity to secrete amines and
hormones. They share similarities with neuroendocrine cells
of the embryological gut. The incidence of GEP-NENs has
increased more than six-fold between 1997 and 2012.1 The
incidence of localised and regional NENs has increased
more than that of NENs with distant metastasis.1 The
incidence of gastroenteropancreatic NETs (GEP-NETs) in the
USA based on an update of the Surveillance, Epidemiology
and End Results (SEER) database is estimated to be 3.56/
100 000/year. The 20-year limited-duration prevalence has
recently been calculated to 48/100 000.1 For incidences of
individual organs, see supplementary Table S1, available at
Annals of Oncology online. In Europe, the incidence of
GEP-NETs has also increased, and ranges between 1.33e
2.33/100 000 population; however, data arise from the
national and regional registries and are heterogeneous and
mostly retrospective.2e4
Men are affected slightly more frequently than women
and show an adverse outcome. Most NENs are well-
differentiated NETs and occur sporadically. GEP-NETs of
the pancreas, duodenum, stomach and, more rarely, NETs of
the thymus and lung may also arise in the setting of the
multiple endocrine neoplasia type 1 (MEN1) syndrome.
Pancreatic NETs (Pan-NETs) are also associated with von
Hippel-Lindau (VHL) disease, tuberous sclerosis (TSC) and
neurofibromatosis. In these hereditary settings, NETs are
multifocal, and the onset of disease is one to two decades
earlier than in sporadic tumours. Furthermore, they are
often early stage at the time of diagnosis. The frequency of
a hereditary background (MEN1, VHL syndromes) was
reported as 5%.5 Recently, whole genomic sequencing
revealed 17% of apparently sporadic Pan-NETs carried
germline mutations also including DNA repair genes (e.g.
MUTYH, CHEK2, BRCA2).6https://doi.org/10.1016/j.annonc.2020.03.304 1
Table 2. Biomarkers
M. Pavel et al.RecommendationsBiomarker Method Use LoE,
GoR
Ki-67 (MIB1) IHC Prognostic relevance, essential
component of the WHO
grading for NENs
IV, A
SSTR-2/5 IHC Detection of somatostatin
receptors when no functional
imaging is possible
IV, C
DAXX/ATRX IHC Prognostic relevance for
Pan-NETs; distinction from NEC
IV, C While most NENs are sporadic, a hereditary background
should be considered, particularly in Pan-NETs.
 Genetic testing should be carried out in patients with
multiple endocrine neoplasias (hyperparathyroidism
and/or pituitary tumours), a family history of NENs or
associated diseases and features suspicious of a heredi-
tary disease, as well as in young patients (<40 years of
age) with gastrinoma [IV, A].
Annals of OncologyP53/pRb IHC Classification of poorly-
differentiated NECs or
distinction from NET G3
IV, C
MGMT IHC, promoter
methylation
assay
Predictive value for
temozolomide response
IV, D
GoR, grade of recommendation; IHC, immunohistochemistry; LoE, level of evidence;
MGMT, O6-methylguanine-DNA methyltransferase; NEC, neuroendocrine carcinoma;
NEN, neuroendocrine neoplasm; NET, neuroendocrine tumour; Pan-NET, pancreatic
neuroendocrine tumour; P53, tumour protein; pRb, retinoblastoma protein; SSTR,
somatostatin receptor; WHO, World Health Organization.
Adapted from Kloeppel8 with permission.DIAGNOSIS AND PATHOLOGY/MOLECULAR BIOLOGY
Histological diagnosis is mandatory in all patients and can
be carried out on resection specimens or core biopsies in
advanced disease. The diagnosis of a NEN is suspected on
hematoxylin eosin (HE)-stained tissue by histomorpho-
logical growth pattern and cytology. The neuroendocrine
phenotype is proven by the immunohistochemical detec-
tion of the neuroendocrine markers synaptophysin and/or
chromogranin A (CgA) [III, A]. Absence of both markers is
very exceptional in a subset of poorly differentiated NECs,
but in this case, other tumour entities must be carefully
excluded. Neuron-specific enolase (NSE) and CD56 markers
are often positive in GEP-NENs, but are not recommended
due to their lack of specificity.7 GEP-NENs should be
classified based on morphology and proliferation (and,
rarely, mutation spectrum) into well-differentiated NETs (G1
to G3) and poorly-differentiated NECs (always G3) (Table 1).
These two classes of NENs reflect biologically and geneti-
cally two different diseases. When showing a high prolifer-
ation rate (>20%), there are clear prognostic differences
between the two classes. Therefore, the World Health
Organization (WHO) 2017 and 2019 classifications split the
heterogeneous G3 GEP-NENs into well-differentiated NET
G3 and poorly-differentiated NEC G3.8,9 Clinical history,
histomorphology and genetics (DAXX/ATRX/MEN1 mutation
in Pan-NET G3, p53 mutation or RB loss in NEC G3) help in
separating the groups (Table 2).8 The separation of
well-differentiated NET G3 from NEC, which had been valid
exclusively for Pan-NENs, has now been adopted forTable 1. WHO 2019 classification for gastroenteropancreatic NENs9
Morphology Grade Mitotic count (2 mm2)a Ki-67 Index (%)b
Well-differentiated NETs G1 <2 <3
Well-differentiated NETs G2 2e20 3e20
Well-differentiated NETs G3 >20 >20
Poorly-differentiated
NECs
 Small-cell
 Large-cell
G3 >20 >20
MiNEN
Tumour-like lesions
HPF, high-power field; MiNEN, mixed neuroendocrine/nonendocrine neoplasm; NEC,
neuroendocrine carcinoma; NEN, neuroendocrine neoplasm; NET, neuroendocrine
tumour; WHO, World Health Organization.
a 10 HPF ¼ 2 mm2, at least 40 fields (at 40 magnification) evaluated in areas of
highest mitotic density.
b MIB1 antibody; percentage of 500e2000 tumour cells in areas of highest nuclear
labelling.
2 https://doi.org/10.1016/j.annonc.2020.03.304gastrointestinal (GI) NENs in an update of the WHO classi-
fication for GI NENs.9 Specific staining for peptide hormones
such as gastrin, insulin, glucagon and amines (serotonin)
can be applied to confirm the source of a clinical symp-
tomatology, but there is no complete agreement between
immunohistochemistry (IHC) and symptomatology, as there
can be synthesis of bioactive compounds without secretion
[non-functioning (NF)-NENs].
IHC for Ki-67 (MIB1) is mandatory to grade the NENs
according to the WHO 2017 and 2019 classifications. Both
the number of mitotic figures per 2 mm2 as well as the Ki-67
index based on assessment of 2000 cells should be reported
(Table 1). In the case of a discordant grade between these
two methods, the higher grade must be attributed.8 Other
biomarkers are optional, such as SSTR-2 staining, in
case functional imaging is not available, or DAXX/ATRX and
p53/RB mutations for discrimination of NET G3 and NEC G3
(Table 2).8 For appropriate pathological diagnosis,
morphology, grading and immunohistochemical staining for
CgA and synaptophysin should be reported [III, A].
NETs arising at different anatomical sites of the digestive
system represent tumour entities that differ in their biology
and clinical presentation (Table 3). Rarely, Pan-NETs may
secrete multiple hormones or NETs may transition from NF
to functional status.10
Recommendation For appropriate pathological diagnosis, morphology,
grading and immunohistochemical staining for CgA and
synaptophysin should be reported. SSTR staining or spe-
cific staining for peptide hormones and amines as well as
use of molecular markers is optional and dependent on
clinical requirements [III, A].
STAGING AND RISK ASSESSMENT
Disease stage and tumour grade are the two major indepen-
dent prognostic parameters and should always be assessed
[III, A]. Since the WHO 2010 classification, NENs are gradedVolume xxx - Issue xxx - 2020
Table 3. Clinical classification of GEP-NETs by site of origin and by hor-
monal secretion
Frequency Symptoms Secretory
product
Intestinal NETs
(carcinoids)
50% of
GEP-NETs
With CS 20% Flushing
Diarrhoea
Endocardial fibrosis
Wheezing
Prostaglandin,
tachykinin, substance P
Serotonin
Serotonin
Histamine, kinins
CgAa
Without CS 80% Unspecific abdominal
pain
CgAa
Pan-NETs 30% of
GEP-NETs
Functioning 10%e30% Zollinger-Ellison
syndrome
Gastrin
Hypoglycaemia Insulin
Necrolytic erythema
Hyperglycaemia
Glucagon
WDHA syndrome VIP
Diabetes, gallstones,
diarrhoea
Somatostatin
Cushing syndrome CRH, ACTH
Acromegaly GHRH, GH
Hypercalcaemia PTHrP
Flushing
Diarrhoea
Calcitoninb
Serotonin
CgAa
NF 70%e90% Unspecific abdominal
pain
Rarely jaundice,
weight loss
CgAa
PPc
ACTH, adrenocorticotropic hormone; CgA, chromogranin A; CRH, corticotropin-
releasing hormone; CS, carcinoid syndrome; GEP-NET, gastroenteropancreatic
neuroendocrine tumour; GH, growth hormone; GHRH, growth hormone-releasing
hormone; GI-NET, gastrointestinal neuroendocrine tumour; NET, neuroendocrine
tumour; NF, non-functioning; Pan-NET, pancreatic neuroendocrine tumour; PP,
pancreatic polypeptide; PTHrP, parathyroid hormone-related peptide; VIP, vasoactive
intestinal peptide; WDHA syndrome, watery diarrhoea, hypokalaemia, achlorhydria.
a CgA is secreted by functioning and NF tumours.
b Calcitonin-secreting tumours may present as NF tumours.
c PP can also be elevated in GI-NETs.
M. Pavel et al. Annals of Oncologyaccording to Ki-67 index and mitotic count (Table 1). For
staging, the tumour, node and metastasis (TNM) staging sys-
tem proposed by the European Neuroendocrine Tumour So-
ciety (ENETS) was recently widely adopted by the eighth
edition of the Union for International Cancer Control/Amer-
ican Joint Committee on Cancer (UICC/AJCC) staging system11
for various types of GEP-NETs. For all NECs, the staging system
of adenocarcinomas must be applied.11 Furthermore, the
primary tumour site has an impact on the prognosis in
advanced disease. Patients with Pan-NETs or colorectal NETs
have a less favourable prognosis than patients with small in-
testinal NETs (SI-NETs) (see supplementary Tables S1eS3,
available at Annals of Oncology online).
Computed tomography (CT) constitutes the basic
radiological method for NET imaging because of its wide
availability, standardised reproducible technique and generally
high diagnostic yield.12 Small metastatic lymph nodes (<1 cm)
mayescape detection by CT. For bonemetastases, CTsensitivity
is poor at 61% (range 46%e80%). Small peritoneal metastases
may be difficult to visualise.13 The sensitivity of CT to detect
NETs is 61%e93% and the specificity is 71%e100%.12,14,15 The
detection rate for liver metastases (LMs) is 79% (73%eVolume xxx - Issue xxx - 202094%),16,17 and for extra-abdominal soft tissue metastases, the
sensitivity is 70% (60%e100%) and specificity 96% (range
87%e100%).18 Magnetic resonance imaging (MRI) is advan-
tageous for examination of the liver and the pancreas and is
usually preferred in the initial staging and for the preoperative
imaging work-up [III, A]. Currently, diffusion-weighted
imaging (DWI) with MRI (DW-MRI), which is based on the
restrictedmovement of water in highly cellular tissues such as
in tumours, is routinely applied and facilitates lesion detec-
tion. The MRI sensitivity to detect Pan NETs is 79% (54%e
100%), with fairly similar detection rates of 76% (61%e
95%),19e21 and for LMs, the sensitivity is 75% (range 70%e
80%) with near maximum specificity of 98%. The mean
sensitivity of MRI for detection of LMs is 91% (range 82%e
98%) as compared with CT with a mean sensitivity of 83%
(range 75%e98%).22e26MRI is also superior to CT for imaging
of the bones and the brain.MRImay, however,miss small lung
metastases, and CT is preferred for imaging of the lungs as it
offers a better spatial resolution.12 Contrast-enhanced ultra-
sound (CEUS) is an excellent method to characterise liver le-
sions that remain equivocal on CT/MRI. When therapy
monitoring is mainly conducted by CT, a three-phase CT
should be carried out. Endoscopic ultrasound (EUS) is the
current optimal imaging method to diagnose small Pan-NETs
with 86% (range 82%e93%) sensitivity and 92% (range
86%e95%) specificity27 and allows also for biopsy, using fine
needle aspiration for cytology or, better yet, a cutting needle
for histopathological diagnosis. Intraoperative ultrasound
(US) facilitates lesion detection/localisation in the pancreas
and liver and is mandatory before pancreatic resection in
MEN1 syndrome patients.
Imaging by 68Ga/64Cu-DOTA-somatostatin analogue (SSA)
positron emission tomography (PET) in combination with CT
(PET-CT) provides high sensitivity for imaging of most types of
NET lesions and should be part of the tumour staging, pre-
operative imaging and restaging [IV, A].12 SSTR scintigraphy
(SRS) should be carried out when PET-CT is not available but is
considerably less sensitive [IV, B]. SRS should include cross-
sectional imaging by single photon emission CT (SPECT)
together with CT (SPECT-CT). The strength of a PET-CT is a
higher detection rate of lymph node, bone and peritoneal
lesions as well as unknown primary tumours.
The sensitivity to detect NET disease by 68Ga-DOTA-SSA-
PET-CT is 92% (range 64%e100%) and specificity 95% (range
83%e100%).28 The sensitivity to detect pancreatic and
duodenal NETs is 92% and the specificity 83%,28 and the
corresponding values for bone metastases are 97%e100%
and 92%e100%.28 The use of PET with [18F]fluoro-deoxy-
glucose (FDG) is optional in NENs. FDG is the tracer of choice
for G3 and high G2 NETs, which generally have higher glucose
metabolism and less SSTR expression than the low-grade
NETs, for which the situation is usually the reverse.29 Com-
bined SSTR imaging and FDG-PET-CT has been shown to be
complementary for lesion detection. Findings of FDG-
positive NETs at PET-CT indicate worse prognosis.29e31
The author panel believes that optimal diagnostic and
prognostic information can be achieved by submitting all
NET G2/G3 patients to PET-CT with both FDG and 68Ga-https://doi.org/10.1016/j.annonc.2020.03.304 3
Annals of Oncology M. Pavel et al.DOTA-SSA (DOTATOC/DOTATATE/DOTANOC); however, this
procedure needs validation and cannot be generally re-
commended, but should rather be adopted on an individual
basis, balancing the potential advantages with the
increasing costs [IV, C].Recommendations Disease stage by TNM classification and tumour grade
are the two major independent prognostic parameters
and should always be assessed [III, A].
 Whole-body SSTR imaging should be part of the tumour
staging, preoperative imaging and restaging [IV, A].
B
68Ga/64Cu-SSTR-PET-CT is recommended but, if not
available, SRS can be used, although it is considerably
less sensitive [IV, B].
B SRS should include cross-sectional imaging by SPECT.
 MRI should be preferred compared with CT for the
detection of liver, pancreas, brain and bone lesions,
while CT is preferred for imaging of the lungs [III, A].
 The use of FDG-PET is optional in NENs and should be
adopted on an individual basis, balancing the potential
advantages with the costs [IV, C].MANAGEMENT OF LOCAL/LOCOREGIONAL DISEASE
Surgery is the treatment of choice for local or locoregional
disease in NET G1 and G2. In functional NETs, clinical
symptoms should be managed before any intervention
[IV, A].Figure 1. Surgical approach in sporadic Pan-NETs.
ASA, American Society of Anesthesiologists; NET, neuroendocrine tumour; Pan-NET,
tumours.
a Slow tumour growth is defined as stable disease by RECIST criteria for >1 year. Surge
options in patients with liver metastases, where applicable.
b To be considered only in exceptional cases (particularly in functioning tumours) in the
(G1eG2, Ki-67 <10%) NET, previous removal of primary tumour, metastatic diffusion
before transplant consideration and age <60 years.
4 https://doi.org/10.1016/j.annonc.2020.03.304Pan-NETs
Preoperative evaluation of localised Pan-NETs should take
into account tumour size, the presence of unspecific
symptoms, functional activity, localisation of the lesion and
signs of local invasiveness (Figure 1).
Several studies demonstrated the safety of a watch-and-
wait strategy instead of surgery for asymptomatic NF-Pan-
NETs 2 cm.32,33 Nevertheless, the shortness of follow-up
and the absence of prospective studies still suggest a
cautious attitude towards this approach.
Currently, a conservative management of incidentally
discovered Pan-NETs 2 cm, consisting of a yearly high-
quality imaging, is suggested for elderly patients, in the
presence of important comorbidities and when a deep
localisation in the head of the pancreas allows only a
pancreaticoduodenectomy [IV, B].33 Surgery is recom-
mended for young patients and in cases when signs of local
invasiveness (e.g. dilation of the main pancreatic duct and/
or presence of jaundice and/or suspicion of nodal involve-
ment) are present. In the latter condition, a standard
pancreatectomy with lymphadenectomy is mandatory,
whereas a parenchyma-sparing resection (e.g. enucleation
or central pancreatectomy) should be routinely considered
when the indication for surgery is related to long life
expectancy. Moreover, surgery is mandatory in the pres-
ence of functioning Pan-NETs irrespective of tumour size.
Curative resection of localised Pan-NETs seems generally
associated with an improved long-term survival and a low
risk of recurrence.34 A standard pancreatectomy (pan-
creatico-duodenectomy or distal pancreatectomy) withpancreatic neuroendocrine tumour; RECIST, response evaluation criteria in solid
ry and/or liver-directed locoregional options may be combined and/or alternative
absence of extrahepatic disease, histological confirmation of a well-differentiated
<50% of the total liver volume, stable disease to therapies for at least 6 months
Volume xxx - Issue xxx - 2020
M. Pavel et al. Annals of Oncologyregional lymphadenectomy35 is recommended for Pan-NETs
>2 cm [IV, A]. Enucleation may represent an alternative
approach to standard pancreatectomy in selected cases.36
Functioning Pan-NETs 2 cm (e.g. insulinomas) represent
ideal lesions to be enucleated, given that they are safely
distant from the main pancreatic duct. The role of enucle-
ation for NF-Pan-NETs is currently limited to selected
patients with small lesions in whom a watch-and-wait
management is contraindicated.
Surgery may also play a role in the presence of
borderline or locally advanced Pan-NETs. Pancreatectomy
with vascular resection is associated with improved out-
comes and it should be carefully considered in the
presence of portal and/or superior mesenteric vein in-
vasion. The presence of other high-risk features (e.g. large
tumour size and/or high-grade Pan-NEC G3) should
discourage an upfront surgical approach [IV, A]. Despite
the lack of evidence, in selected patients with high-risk
features, a neoadjuvant treatment may be considered.
The role of surgery for localised Pan-NEC G3 is still
controversial, as upfront surgery may not have a clear
benefit in terms of survival.37
For Pan-NETs in patients affected by MEN1 syndrome, see
Section 1 of supplementary Material, available at Annals of
Oncology online.Figure 2. Surgical approach in SI-NETs.
NET, neuroendocrine tumour; RECIST, response evaluation criteria in solid tumours; S
a Slow tumour growth is defined as stable disease by RECIST criteria (for >1 year
alternative options in patients with liver metastases, where applicable.
b To be considered only in exceptional cases (particularly in functioning tumours) in the
(G1eG2, Ki-67 <10%) NET, previous removal of primary tumour, metastatic diffusion
months before transplant consideration and age <60 years.
Volume xxx - Issue xxx - 2020SI-NETs
Macroscopic radical resection of localised SI-NETs reduces
the risk of intestinal complications (bowel obstruction and
ischaemia), is associated with improved outcomes38 and is
recommended along with systematic mesenteric lympha-
denectomy [IV, A] (Figure 2). Surgical indication for SI-NETs
is influenced by the multifocality of these lesions and by the
high likelihood of nodal involvement.39 During surgery for
SI-NETs, an accurate palpation of the entire intestine and a
systematic lymphadenectomy (at least 8 nodes) are
mandatory.39,40 The frequent presentation at an emergency
setting as well as the rarity of the disease increase the risk
of an inadequate surgical resection. Surgery is also generally
recommended in the presence of locally advanced SI-NETs,
as the presence of a large mesenteric mass can cause acute
or chronic intestinal obstruction and/or localised/diffuse
intestinal ischaemia [V, B]. In these cases, a macroscopic
radical resection of primary SI-NETs and regional lymph
nodes can be achieved in 80% of cases if carried out by
experienced surgeons.40Recommendations Surgery is the treatment of choice for local or locore-
gional disease in NET G1 and G2. Before anyI-NET, small intestinal neuroendocrine tumour.
). Surgery and/or liver-directed locoregional options may be combined and/or
absence of extrahepatic disease, histological confirmation of a well-differentiated
<50% of the total liver volume, stable disease on medical therapies for at least 6
https://doi.org/10.1016/j.annonc.2020.03.304 5
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6intervention, medical treatment is required in function-
ally active tumours [IV, A].
 For NF-Pan-NETs 2 cm, a conservative approach with
surveillance consisting of yearly, high-quality imaging is
suggested [IV, B].
 For Pan-NETs >2 cm, the risk of nodal metastases is
increased, therefore, a standard pancreatectomy (pan-
creaticoduodenectomy or distal pancreatectomy) with
regional lymphadenectomy is recommended [IV, A].
 The presence of high-risk features (e.g. large borderline
tumour size and/or high-grade Pan-NEC G3) should
discourage an upfront surgical approach [IV, A].
 NF-Pan-NETs in the setting of MEN1 syndrome are often
stable or slow growing; therefore, a watch-and-wait
management of these tumours can be safely adopted
when 2 cm in size [IV, A].
 When surgery is indicated, a minimally invasive approach
is recommended whenever feasible [IV, B].
 Macroscopic radical resection of localised SI-NETs is
recommended along with systematic mesenteric
lymphadenectomy [IV, A].
 Surgery is also recommended in the presence of locally
advanced SI-NETs, as the presence of large mesenteric
mass can cause acute or chronic intestinal obstruction
and/or localised/diffuse intestinal ischaemia [V, B].MANAGEMENT OF ADVANCED/METASTATIC DISEASE
Surgery for metastatic disease
Given the relatively indolent behaviour of a large fraction of
GEP-NETs, surgery also plays a role in metastatic disease.41
A surgical approach is indicated in selected patients affected
by stage IV GEP-NETs who have exclusive or predominant
liver involvement, after having carefully evaluated the
tumour grading, distribution of LMs and primary site [IV, B].
Upfront surgery should be excluded in the presence of
extra-abdominal metastases and high-grade GEP-NENs [IV,
B].42 It seems reasonable to consider the presence of an
advanced NEC G3 as an absolute contraindication for sur-
gery [IV, A], whereas NET G3 should not be excluded a
priori.
Another crucial parameter for considering a surgical
approach is the distribution of LMs.43 Surgical resection
should be attempted in the presence of resectable or
potentially resectable LMs.43 A curative resection (R0, R1) of
GEP-NETs with LMs is associated with a 5-year overall sur-
vival (OS) rate of around 85%.41 Preselection biases due to
better performance status (PS) or less advanced disease are
likely to influence this result. GEP-NET LMs are frequently
more extensive than those which are identified, even
intraoperatively, and a real curative resection is difficult to
achieve. The role of palliative resection is controversial
when multiple, unresectable LMs are present. Primary site
and presence of symptoms are important factors to be
considered before planning a possible palliative surgical
resection.https://doi.org/10.1016/j.annonc.2020.03.304Palliative resection of primary SI-NETs in advanced dis-
ease is generally indicated for preventing complications
related to bowel obstruction or intestinal ischaemia [IV, C].
However, it is controversial if primary tumour removal in
patients with stage IV disease translates to an improvement
in survival. A recent large single-centre experience
demonstrated no survival benefit in patients with stage IV
disease after prophylactic palliative SI-NET resection,
compared with no or delayed resection when needed.44
The role of debulking surgery in advanced NF-GEP-NETs is
unclear.38,41 Debulking surgery is recommended for allevi-
ating symptoms of the carcinoid syndrome (CS) in patients
affected by metastatic functioning SI-NETs [IV, B]. In those
patients with symptoms related to tumour burden,
debulking surgery may also be of benefit.
Patients with high tumour burden of functioning Pan-
NETs may benefit from debulking surgery [e.g. insulinoma,
vasoactive intestinal peptide (VIP)oma], and surgery is
generally recommended for this indication [IV, B]. The need
for palliative resection of NF-Pan-NETs is debated, as the
risk of tumour-related symptoms is low and is not consid-
ered in patients with Ki-67 >10% [IV, B]. Despite this, recent
evidence from retrospective series suggested that primary
Pan-NET resection is associated with better long-term
outcomes.45
Nevertheless, the potential advantage of palliative
surgery, either primary tumour resection or debulking
surgery in advanced GEP-NETs is controversial in terms of
survival and underlies the bias of preselection of better
prognosis patients for surgery.
Liver transplantation may be a valid option in very
selected patients with unresectable LMs when the following
criteria are met: absence of extrahepatic disease, histo-
logical confirmation of a well-differentiated (G1/G2, Ki-67
<10%) NET, previous removal of primary tumour, meta-
static diffusion <50% of the total liver volume, stable dis-
ease in response to therapy for at least 6 months before
transplant consideration and age <60 years [IV, B].20 In
these selected patients with good baseline prognostic
factors, a 5-year OS of 69%e97.2% has been reported.46
Liver transplantation is preferably considered in patients
with functioning tumours (CS refractory to systemic thera-
pies due to high liver tumour burden and in those affected
by SI-NETs who usually exhibit a more favourable prog-
nosis). Liver transplantation should be thoroughly discussed
within a NET-dedicated multidisciplinary team, carefully
considering all the alternative therapeutic options.
In patients with LMs who are ineligible for complete
surgical resection, vascular and ablative locoregional
modalities can be considered as an alternative to surgery.
Locoregional therapies are discussed in detail in Section 2 of
supplementary Material, available at Annals of Oncology
online. Locoregional treatments can also be considered as
alternative therapy to LM resection in patients with
resectable LMs [V, C]. Combining resection and radio-
frequency ablation (RFA) may provide the opportunity to
achieve complete tumour removal, allowing more limitedVolume xxx - Issue xxx - 2020
M. Pavel et al. Annals of Oncologyresections when otherwise more extensive hepatectomies
could compromise residual liver function.
Adjuvant therapy
There are no data to support adjuvant therapy in NET G1/
G2, as data from prospective randomised clinical trials
(RCTs) are lacking [IV, A]. However, in aggressive NENs (NEC
G3), adjuvant therapy with platinum-based chemotherapy
(ChT) can be considered [V, C]. Prospective clinical trials are
warranted.
Medical therapy
The goal of systemic therapy is to control the tumour-
associated clinical symptoms and the tumour growth [I, A].
Treatment for symptom control. The use of SSAs (octreo-
tide, lanreotide) is standard first-line therapy in functioning
NETs.47 Improvement of flushing and diarrhoea is achieved
in 70%e80% of patients by using slow-release formulations
[I, A]. SSAs are in general well tolerated except for mostly
transient GI side-effects (diarrhoea, abdominal discomfort,
flatulence, nausea). In case of radiological stable disease or
slow growth and worsening CS, it is common practice to
increase the SSA dose to greater than the standard dose
[octreotide long-acting release (LAR) 30 mg intramuscular
(i.m.) once every 4 weeks (q4w), lanreotide autogel (AG)
120 mg subcutaneous (s.c.) q4w] by shortening the injec-
tion interval to 3 or even 2 weeks of long-acting SSAs to
alleviate symptoms48 although sufficient prospective data
are lacking to support this approach [IV, C]. Rescue s.c.
octreotide injections are used alternatively, particularly in
cases of intermittently increased symptoms. Pasireotide
LAR, a universal ligand to SSTR, may be considered off-label
based on its efficacy in subsets of patients with CS when
established options failed.49 Furthermore, interferon alpha
(IFN-a) is approved for symptom control (3e5 million IU s.c.
three times weekly) with similar efficacy compared with
SSA, but it is usually used in second-line as an add-on
treatment to SSA in patients with refractory syndrome,
due to its less favourable toxicity profile (fatigue, weight
loss and, more rarely, depression) [II, B].50
Telotristat ethyl is an oral inhibitor of tryptophan
hydroxylase, a rate-limiting enzyme in the synthesis of
serotonin, that has demonstrated a significant improve-
ment in the number of bowel movements in a phase III
trial (TELESTAR) with 135 patients with refractory CS
diarrhoea (4 bowel movements per day) compared with
placebo. Durable response (defined as 30% improvement
in bowel movements for >50% of the 12-week core study
period) occurred in 44% and 42% of the patients treated
with 250 mg or 500 mg three times a day (t.i.d.),
respectively.51 A second placebo-controlled trial (TELE-
CAST) including patients with less frequent bowel move-
ments supports the efficacy and good tolerability of
telotristat ethyl. Adverse effects include mild elevations of
liver enzymes. Depression-related events and nausea were
observed at higher doses.52 Patients with durable responseVolume xxx - Issue xxx - 2020showed significant and/or meaningful improvements in
global quality of life (QoL), as well as nausea, pain,
diarrhoea and other GI symptoms.53 Telotristat ethyl (250
mg t.i.d.) is approved for treatment of diarrhoea associ-
ated with CS in patients insufficiently controlled with SSA
and can be recommended for this indication as an add-on
treatment to SSA [I, A].
In progressive disease, peptide receptor radionuclide
therapy (PRRT) may be considered to improve symptoms
[II, B], although efficacy may not be durable
(Figure 3).54,55 With regard to the CS in the NETTER-1
study, diarrhoea (present in 48% and 53% in the two
treatment arms) improved equally in 48% and in 43% of
the patients in the lutetium-177 (177Lu)-DOTATATE þ
octreotide LAR 30 mg arm versus octreotide LAR 60 mg
arm, respectively; however, the time to deterioration
(TDD) in QoL for diarrhoea after PRRT is significantly
better than the TTD in the control arm. There was no
difference in control of other symptoms including flush-
ing.55 Noteworthy, acute aggravation of symptoms may
occur during or after PRRT (such as worsening of hypo-
glycaemia in insulinoma or diarrhoea in CS) and requires
careful observation [IV, A]. More data are needed to best
select treatment options in refractory CS, either dose
escalation of SSA or add-on of another treatment (e.g.
telotristat ethyl, IFN-a, PRRT).
Other treatment options for uncontrolled symptoms
include everolimus, particularly in metastatic insulinoma,
but also refractory CS with progressive disease, although it
is not approved in this indication by either the European
Medicines Agency (EMA) or the Food and Drug Associa-
tion (FDA) [IV, B]. Diazoxide is of value in metastatic
insulinoma, as it inhibits the secretion of insulin by
tumour cells; SSA should be used under surveillance for
the risk of worsening hypoglycaemia. Metastatic gas-
trinoma may be well controlled with proton pump in-
hibitors (PPIs) alone over the long term; in uncontrolled
Zollinger-Ellison syndrome, SSAs may be used.56 SSAs are
a standard of care in patients with other functioning Pan-
NETs such as NET secreting VIP, glucagon and other
bioactive compounds (Table 3). PRRT is an effective
treatment for symptom control in functional Pan-NETs
refractory to SSA.57
Antiproliferative treatment. Predictive factors for therapy
selection are lacking. The choice of antiproliferative treat-
ment is based on pathological and clinical features, tumour
extent, growth behaviour and SSTR imaging. Furthermore,
the sequential use of drugs is impacted by the evidence
level of drug activity, patient comorbidities and accessibility
to drugs in different countries.
Antiproliferative medical treatment options include
targeted drugs and systemic ChT. SSAs and IFN-a (also
named biotherapy) are the oldest targeted drugs used in
NETs while novel targeted drugs, such as the mammalian
target of rapamycin (mTOR) inhibitor everolimus and the
multiple tyrosine kinase inhibitor (TKI) sunitinib, have been
introduced more recently in the management of NETs. Nonehttps://doi.org/10.1016/j.annonc.2020.03.304 7
Figure 3. Therapeutic approach in NETs with carcinoid syndrome.
177Lu, lutetium-177; IFN-a, interferon alpha; LAR, long-acting release; NET, neuroendocrine tumour; PRRT, peptide receptor radionuclide therapy; RFA, radiofrequency
ablation; s.c., subcutaneous; SIRT, selective internal radiotherapy; SSA, somatostatin analogue; SSTR, somatostatin receptor; TACE, transarterial chemoembolisation;
TAE, transarterial embolisation; TE, telotristat ethyl.
a SSAs can be tried in SSTR-negative patients, particularly if tumour burden is very low and/or lesion size is very small (potentially false-negative SSTR status).
b Long-acting SSAs should be interrupted at least 4 weeks before PRRT and should be continued ‘not earlier than’ 1 h after PRRT cycle(s).
c PRRT may be considered in patients without prior tumour progression but with high tumour burden and uncontrolled diarrhoea (off-label).
d Above labelled dosages [shortening of the injection interval of long-acting SSAs (lanreotide 120 mg; octreotide 30 mg) to every 3 or 2 weeks instead of every 4 weeks]
(off-label) or short-acting octreotide s.c. as additional injections.
e IFN-a should be interrupted if PRRT is considered.
f TE can be continued with other treatments if patient has a benefit; it is not an option if patient has predominant flushing.
Annals of Oncology M. Pavel et al.of the available treatment options provides a cure, but
rather disease stabilisation with variable duration,
depending on different prognostic factors including grade,
tumour extent and slope of progression.
Somatostatin analogues. SSAs are an established anti-
proliferative therapy in metastatic GEP-NETs, based on two
placebo-controlled trials. Most frequently, they are used in
first-line treatment, based on their modest activity and the
settings in which they have been studied. Overall response
rates (ORRs) are low (<5%). The PROMID study showed
prolongation of time to tumour progression (TTP) in
therapy-naive advanced metastatic midgut NETs (mostly G1
and with low tumour burden) by 8.3 months; TTP with
octreotide LAR 30 mg was 14.3 months and 6 months with
placebo.588 https://doi.org/10.1016/j.annonc.2020.03.304The CLARINET study demonstrated efficacy not only in
midgut but also in Pan-NETs and NETs with high liver
tumour burden (>25%), and NET G2 with a Ki-67 of 10%.
Most patients (96%) had stable disease at study onset. The
median progression-free survival (PFS) was not reached
with lanreotide (>27 months) and was 18 months in the
placebo arm.59 The CLARINET extension study also showed
efficacy in progressive disease patients with entero-
pancreatic NETs.60 There is very good long-term tolerability
of both SSAs.47,58,59 SSAs can be recommended for tumour
growth control in advanced SSTR-positive, slowly-growing
GI and Pan-NETs up to a Ki-67 of 10% [I, A; European Society
for Medical Oncology-Magnitude of Clinical Benefit Scale
(ESMO-MCBS) v1.1 score: 3] for lanreotide and [I, A; ESMO-
MCBS v1.1 score: 2] for octreotide. SSAs can be recom-
mended in patients with unknown disease status, stable orVolume xxx - Issue xxx - 2020
M. Pavel et al. Annals of Oncologyprogressive disease. Tumour burden may impact the treat-
ment onset. Positive SSTR status is generally required but is
not predictive of response, and SSTR imaging, particularly
SRS, may miss small lesions of <1 cm in size. Since OS
benefit is lacking in both SSA trials (CLARINET OS data are
still premature), probably due to high crossover rates,59,61
and patients with indolent tumour behaviour may have
stable disease for long time, a watch-and-wait strategy may
be applied, particularly in patients with NET G1 and/or low
tumour burden (<10% liver tumour burden and absence of
extra-abdominal disease) and stable disease [IV, A]. A
watch-and-wait approach is less frequently applied in
advanced Pan-NETs, the majority of the patients have NET
G2 rather than NET G1.
IFN-a. Based on long-term experience in NETs50 and
supported by recent results from a large randomised trial
(including 35% midgut NET, median PFS 15.4 months for
IFN-a and octreotide LAR),62 IFN-a can be considered for
antiproliferative therapy if other treatment options have
been exploited or are not feasible (e.g. SSTR-negative status
on functional imaging), particularly in midgut NETs, where
there are fewer options as compared with Pan-NETs [IV, B].Everolimus. Everolimus has been studied extensively at a
dose of 10 mg/day in various subtypes of NENs and has
shown activity in Pan-, GI and pulmonary NETs. ORRs are
low (<10%) with everolimus. Three prospective studies
demonstrate a high disease control rate with everolimus in
Pan-NETs. Median PFS ranges from 9.7 months in heavily
pretreated patients (RADIANT-1 study) to 16.6 months in
patients with few prior therapies.63,64
The registration trial (RADIANT-3 study) with 410 patients
(including 40% therapy-naive patients) showed prolonga-
tion of PFS by 6.4 months in advanced progressive Pan-
NETs; median PFS was 11 months with everolimus and 4.6
months with placebo.65 There was a trend toward OS
benefit.66 Everolimus is recommended in progressive Pan-
NET G1/G2 with or without prior ChT [I, A; ESMO-MCBS
v1.1 score: 3]. Addition of the SSA pasireotide to
everolimus did not provide a more durable benefit
compared with everolimus alone in progressive Pan-NETs
(COOPERATE-2 study)64; thus, combination therapy of SSA
and everolimus is not recommended [II, D]; exceptions may
be functioning Pan-NETs. The positioning of everolimus in
the treatment algorithm for progressive Pan-NETs is further
studied in comparison with PRRT (COMPETE) and strepto-
zotocin (STZ)-based ChT (SEQTOR) in ongoing clinical trials
(NCT03049189, NCT02246127).
The efficacy of everolimus in advanced NF-GI NETs with
poor prognosis has been demonstrated by the RADIANT-4
trial.67 In this trial, 302 patients with GI and lung NETs
were included. Median PFS was 11 months with
everolimus and 3.9 months with placebo [hazard ratio
(HR) 0.48]. There was a benefit in terms of PFS prolon-
gation in the GI subgroup [HR 0.56 (0.37e0.8)] and the
lung NET subgroup [HR 0.5 (0.28e0.88)], and everolimus is
EMA-approved for NF-GI and lung NETs. Everolimus shouldVolume xxx - Issue xxx - 2020be used in patients with clearly progressive GI NETs [I, A;
ESMO-MCBS v1.1 score: 3]. The efficacy derived from a
post hoc analysis revealed heterogeneous response pat-
terns among GI NETs with limited benefit in indolent ileum
NET.68 The author panel recommends the use of evero-
limus after PRRT in SI-NETs, when PRRT is available [V, A].
However, the treatment sequence needs to be further
studied in the absence of definite predictors of response.
Health-related QoL evaluation in the overall study popu-
lation, as measured by the Functional Assessment of
Cancer Therapy-General Questionnaire (FACT-G) did not
identify statistically significant improvement with evero-
limus as compared with placebo.69,70
The use of everolimus is less clear in patients with
advanced NETs (carcinoids) associated with CS. Although a
prolongation of PFS had been shown with everolimus in
combination with octreotide compared with placebo and
octreotide, the result was not statistically significant (by
central reading) and everolimus is not registered for pa-
tients with functioning NETs71; nevertheless, clinically
beneficial effects have been reported in CS patients. Of
note, the final OS results from the RADIANT-2 trial indicate a
trend toward unfavourable OS in the everolimus arm,
although not statistically different from the placebo arm.
Everolimus should be used with caution if considered for
patients with CS.72
Most frequent and relevant side-effects include stomatitis
(>60%), diarrhoea (w30%), fatigue (w30%), infections
(20%e29%), pneumonitis (12%e16%) and hyperglycaemia
(10%e13%). A referral to the summary of product character-
istics is recommended.73 Across all randomised everolimus
trials, drug-related adverse events were mostly manageable.
However, around 60% required dose reduction or treatment
interruption.65,67,71 Life-threatening side-effects may occur in
individual patients (e.g. serious infections, sepsis, thrombo-
embolic events) and require comprehensive patient education
and regular careful follow-up investigations while patients are
on everolimus treatment.
There are no data to support the use of everolimus in
NECs. However, small retrospective studies indicate some
value in Pan-NET G3.74 Prospective phase II trials are
ongoing to assess the activity of everolimus in NET G3 and
NECs (NCT02113800, NCT02248012).
Sunitinib. Sunitinib is the only multiple TKI that is EMA-
approved in Pan-NETs [I, A; ESMO-MCBS v1.1 score: 3]. In
a randomised trial, sunitinib (37.5 mg/day) was compared
with placebo in 171 patients with advanced unresectable
Pan-NETs. A significantly longer PFS (11.4 versus 5.5
months) was noticed in favour of sunitinib [I, A].75 ORR was
<10%; there was a trend toward an OS benefit with
sunitinib.76 While treatment was associated with modest
side-effects, there was no significant improvement in
multiple QoL domains, but worsening of diarrhoea with
sunitinib versus placebo.77 Most frequent side-effects
include diarrhoea (59%), nausea (45%), asthenia (34%),
vomiting (34%) and fatigue (32%). Other side-effects include
hypertension (26%), lymphopaenia (26%) and hair colourhttps://doi.org/10.1016/j.annonc.2020.03.304 9
Annals of Oncology M. Pavel et al.changes (29%); referral to the summary of product
characteristics is recommended.78 Results of a phase IV trial
confirm the efficacy and safety of sunitinib in patients with
advanced, well-differentiated Pan-NETs who were
treatment-naive or previously treated with other drugs.79
Sunitinib is recommended in the management of
advanced progressive Pan-NETs [I, A]. The drug has no
indication in Pan-NECs due to the lack of data. Promising
data from a small phase II study in patients with NET G3 and
NEC80 need to be validated in a larger study.
The appropriate sequencing of targeted drugs remains
unclear and is mostly dependent on patient individual
factors including comorbidities and side-effects of targeted
drugs. There are no data to support the use of TKIs outside
of clinical trials in GI NETs. However, recent data from a
phase III placebo-controlled trial (SANET-ep) indicated
activity of surufatinib in extra-Pan-NETs in a Chinese pop-
ulation; surufatinib prolonged PFS by 5.4 months compared
with placebo in poor prognosis patients (>80% NET G2,
most frequent primary sites include the rectum and lung).81
Ongoing randomised controlled trials will provide more
data on TKIs in the future (see Section 3 of supplementary
Material, available at Annals of Oncology online).
Systemic ChT. The use of systemic ChT is recommended in
advanced Pan-NETs and in NEN G3 of any site [II, A]. Results
with systemic ChT for advanced well-differentiated
non-pancreatic NETs of the GI tract are poor; in a system-
atic review of patients with locally advanced or metastatic
well-differentiated G1/G2 GI NETs, the ORR was 11.5%
(range 5.8%e17.2%)82; thus, ChT cannot be recommended
in this setting [II, C]. Preselection of patients with higher
probability of response (e.g. higher Ki-67 in the range of
15%e20%; significant progression) might be associated
with benefit from ChT. Systemic ChT may be considered
under these conditions in individual cases [V, C] (Figure 4).
Systemic ChT is indicated in patients with non-resectable
LMs and/or other distant metastases from G1/G2 Pan-NETs
using a combination of STZ and 5-fluorouracil (5-FU) [II, A].
ORRs range between 35% and 40%. STZ-based ChT can be
considered upfront in bulky disease without documented
prior tumour progression. Recent retrospective analyses
from European centres support the efficacy demonstrated
in RCTs carried out a long time ago.83e85 From retrospective
trials, temozolomide (TEM)-based ChT is active in Pan-NETs,
either alone or combined with capecitabine (CAP)86;
preliminary results from the prospective explorative two-
arm phase II trial of CAPTEM versus TEM in patients (n ¼
145) with progressive Pan-NETs confirm the efficacy of TEM-
based ChT and suggest superiority of the combination
therapy (CAPTEM) compared with TEM alone with respect
to PFS prolongation (22.7 months versus 14.4 months,
respectively; HR 0.58, P ¼ 0.023) [II, B].87 However, un-
balanced low-grade NETs and a longer time since diagnosis
to therapy in favour of the combination arm may have
impacted the results. ORRs were not different with TEM
(27.8%) versus CAPTEM (33.3%). The value of using O(6)-
methylguanine-DNA methyltransferase (MGMT) expression10 https://doi.org/10.1016/j.annonc.2020.03.304or promoter methylation for preselection of patients is
controversial.86,88
In cases of liver and/or other distant metastases from
high-grade small or large-cell NEC G3 regardless of the
primary tumour origin combination ChT, using cisplatin/
etoposide or carboplatin/etoposide is recommended [III, A].
Although ORRs may be high (30%e67%), median OS (mOS)
is very limited (11e19 months). Early treatment onset is
crucial for the outcome. There is no established second-line
therapy for poorly differentiated NECs, but retrospective
studies from single centres indicate some efficacy of TEM
alone or in combination with CAP  bevacizumab, of 5-FU
intravenously or CAP orally, combined with either oxalipla-
tin or irinotecan [IV, B].89,90
The ORR with cisplatin-based ChT in NET G3 (in general,
Ki-67 is <55%) is much lower than in NEC and cisplatin/
etoposide is not recommended [IV, C]. Other options may
be considered including TEM, targeted drugs, PRRT in
selected cases and STZ-based ChT in the case of Pan-NETs
(Figure 4).
PRRT. PRRT is a therapeutic option in progressive SSTR-
positive NETs with homogenous SSTR expression (all NET
lesions are positive) assessed by SSTR imaging.91,92 The two
peptides most commonly used for PRRT are DOTATOC and
DOTATATE. 177Lu is increasingly preferred to yttrium-90
(90Y)-labelled SSA due to its much lower kidney toxicity
and the possibility to carry out scintigraphy and thus
dosimetry.
Recently, the multicentre prospective phase III NETTER-1
trial has compared 177Lu-DOTATATE (7.4 GBq every 8
weeks, four intravenous infusions) in association with 30 mg
octreotide LAR versus 60 mg octreotide LAR alone (every 4
weeks) in 229 patients with metastatic well-differentiated
(G1/G2) midgut NETs.93 Patients had progressive disease
within a time frame of up to 3 years, and all had previously
been treated with a standard dose of SSA. 177Lu-DOTATATE
was superior to high-dose octreotide in terms of PFS (pri-
mary end point). Median PFS (mPFS) with 177Lu-DOTATATE
was 28.4 months while it was 8.5 months with high-dose
octreotide (HR for disease progression 0.214; 95% CI
0.139e0.331).94 177Lu-DOTATATE was also associated with
a higher ORR (18% versus 3%) at 3 months after the fourth
PRRT cycle. OS analysis is premature and indicates a trend
towards OS benefit.93,94 Treatment was also associated with
an improvement in symptoms and time to QoL deteriora-
tion for global health status, physical functioning, fatigue,
pain and diarrhoea.55 PRRT can be recommended in pa-
tients with midgut NETs with disease progression on SSAs
who fulfil the general requirements for PRRT that are
reported elsewhere [I, A].95 PRRT can also be considered at
further therapy lines and in NETs from other sites than
midgut (Figure 4). Several phase II trials and observational
studies that recruited more than 1000 patients reported
overall ORRs ranging between 4% and 39% in patients
with both functioning and NF-SSTR-positive NETs including
NETs of the pancreas or GI tract outside the midgut
region.54,96e98 177Lu-DOTATATE has been approved byVolume xxx - Issue xxx - 2020
Figure 4. Systemic therapy in GEP-NENs.
The stratification factors are not predictive, but prognostic.
A watch-and-wait approach is recommended in asymptomatic low-grade tumour patients with absence of morphological progression. Locoregional therapy may be
considered as an alternative approach to systemic therapies in SI- and Pan-NETs in liver disease only or predominant liver disease if extrahepatic lesions are stable.
Locoregional therapy may also be considered early in NET G2 patients and advanced disease.
In Pan-NET G3 with moderate Ki-67, the treatment is similar to Pan-NET G2. The choice of ChT is mainly based on the tumour growth rate and Ki-67. STZ-based and TEM-
based therapies provide similar ORRs, although a comparative study is not available.
STZ has been combined with doxorubicin in Pan-NETs and produced high ORRs, but its use is limited due to potential cardiotoxicity to maximal cumulative dose of 400
mg/m2.
One author (EPK) indicates that in SSTR-positive Pan-NET G1/G2 (Ki-67 <10%) PRRT might be considered after first-line SSA or chemotherapy, equal to the choice of
targeted drugs and that in SI NET G2 (Ki-67>10%) PRRT could be considered equal to everolimus.
Green arrows indicate progressive disease.
5-FU, 5-fluorouracil; CAP, capecitabine; CAPTEM, capecitabine and temozolomide; ChT, chemotherapy; EVE, everolimus; FOLFIRI, 5-fluorouracil/leucovorin/irinotecan;
FOLFOX, 5-fluorouracil/leucovorin/oxaliplatin; GEP-NEN, gastroenteropancreatic neuroendocrine neoplasm; IFN-a, interferon alpha; NEC, neuroendocrine carcinoma;
NET, neuroendocrine tumour; ORR, overall response rate; Pan-NET, pancreatic neuroendocrine tumour; PRRT, peptide receptor radionuclide therapy; RECIST, response
evaluation criteria in solid tumours; SI, small intestinal; SI-NET, small intestinal neuroendocrine tumour; SSA, somatostatin analogue; SSTR, somatostatin receptor; STZ,
streptozotocin; SUN, sunitinib; TEM, temozolomide.
a Slow tumour growth is defined as stable disease by RECIST criteria for >1 year.
b In liver-dominant disease.
c If PRRT is not available, everolimus can be used as second-line therapy.
d Rapid growth is defined as RECIST progression within a year or less.
e In liver-only disease or predominant liver disease.
f If SSTR-positive.
M. Pavel et al. Annals of Oncologythe EMA and the FDA, not only in patients with midgut
NETs [I, A; ESMO-MCBS v1.1 score: 4] but also in patients
with Pan-NETs [III, A; ESMO-MCBS v1.1 score: 4]. Results
from RCTs with PRRT in Pan-NETs are lacking and molecular
targeted agents, such as everolimus or sunitinib, and sys-
temic ChT may therefore be preferred treatment choices,
and PRRT after failure of these approved therapies [III, A]
(Figure 4). However, one author (EPK) feels that PRRT
should be considered earlier in the treatment algorithm for
SSTR-positive Pan-NETs.Volume xxx - Issue xxx - 2020For more information about selection criteria and PRRT
biomarkers, see Section 4 of supplementary Material,
available at Annals of Oncology online.
The published data on results of PRRT in NEN G3 of about
280 patients in four retrospective studies with a number of
patients ranging between 28e149 with Ki-67 >20% support
the therapeutic consideration of PRRT also in this group of
patients.99e102 The overall results show disease control
rates between 30% and 80%, PFS 9e23 months and OS 19e
53 months. The results were significantly better in patientshttps://doi.org/10.1016/j.annonc.2020.03.304 11
Annals of Oncology M. Pavel et al.with a Ki-67 <55% compared with those with higher Ki-67
values (there are fewer patients with a Ki-67 >55%). In
patients with a Ki-67 of >35%, mPFS was 6.8 months in one
study,101 and in patient subgroups with Ki-67 >55%, mPFS
was 6 months, 4 months and 4 months, respectively from
the different studies.99,100,102 PRRT may be considered in
patients with NET G3 [IV, C], however, patients need to be
carefully selected and prospective trials are warranted to
further establish which patients with NEN G3 might benefit
most from PRRT. The NETTER-2 trial has recently been
initiated to address this issue (NCT03972488).
Treatment with 177Lu-DOTATATE is in general considered
safe, however, up to 3%e4% of the patients may develop
irreversible bone marrow toxicity such as leukaemia or bone
marrow dysplasia. Mild renal toxicity grade 1/2 has been re-
ported long term in 30% of the patients (see Section 5 of
supplementary Material, available at Annals of Oncology
online).
For more information about PRRT and SSA combination
and maintenance therapy, see Section 6 of supplementary
Material, available at Annals of Oncology online.Recommendations A surgical approach is indicated in selected patients
affected by stage IV GEP-NETs who show exclusive or pre-
dominant liver disease after careful evaluation of tumour
grading, distribution of LMs and primary site [IV, B].
 Upfront surgery is not indicated in the presence of extra-
abdominal metastases and high-grade GEP-NENs [IV, B].
 Presence of an advanced NEC G3 is considered an abso-
lute contraindication for an upfront surgery [IV, A].
 Palliative resection of primary SI-NETs in advanced dis-
ease is generally indicated for preventing complications
related to bowel obstruction or intestinal ischaemia [IV,
C]. However, it is controversial if primary tumour
removal in patients with stage IV disease translates to
an improvement in survival.
 Debulking surgery is recommended for alleviating symp-
toms in patients affected by metastatic functioning
SI-NETs [IV, B].
 In advanced Pan-NETs with uncontrolled symptoms
related to hormone hypersecretion, debulking surgery
may be indicated [IV, B], but is generally not considered
in patients with Ki-67 >10% [IV, B].
 Liver transplantation may be a valid option in very
selected patients with unresectable LMs [IV, B].
 Locoregional treatments can be considered as an
alternative therapy to LM resection in patients with
resectable LMs [V, C].
 Adjuvant therapy is not indicated in NET G1/G2 [IV, A].
However, in aggressive NENs (NEC G3), adjuvant therapy
with platinum-based ChT may be considered [V, C].
 Vascular and ablative locoregional treatments are valid
options for treatment of LMs, also in conjunction with
other systemic therapies or in combination with surgery.
The choice of the procedures depends on the local12 https://doi.org/10.1016/j.annonc.2020.03.304expertise, the extension and vascularisation of LMs and
the localisation of liver involvement [V, C].
 In functional NETs, locoregional therapies should be
applied early, following SSA therapy, to further improve
control of hormonal symptoms and prevent complica-
tions (e.g. carcinoid crisis in serotonin-secreting NETs)
[IV, A].
 In patients with NF-NETs with disease limited to the liver,
locoregional therapies can be considered as an alterna-
tive to systemic treatment [IV, B].
 Systemic therapy should be administered to control
tumour-associated clinical symptoms and tumour growth
[I, A].
 The use of SSAs is standard first-line therapy in patients
with CS and some rare functional Pan-NETs (e.g. VIPoma,
glucagonoma) [I, A].
 In patients with refractory diarrhoea related to CS, telo-
tristat ethyl can be recommended as an add-on treat-
ment to SSAs [I, A].
 SSA dose increase is an alternative approach to improve
symptoms in refractory CS [IV, C], as well as the use of
IFN-a, although it is less well tolerated [II, B].
 In progressive disease, PRRT may have a significant
impact on diarrhoea control in patients with CS [II, B].
 Hormonal crisis may occur soon after PRRT and requires
careful information to be given to the patient before and
directly after PRRT, and eventually admission and proper
treatment [IV, A].
 The choice of antiproliferative treatment is based on
pathological and clinical features, tumour extent, growth
behaviour and SSTR imaging.
 A watch-and-wait strategy may be followed in patients
with low Ki-67 (<2%), low tumour burden and stable
disease [IV, A], preferably in SI-NETs with long-term
favourable prognosis.
 SSAs can be recommended as first-line therapy for
tumour growth control in advanced, slowly-growing
SSTR-positive GI and Pan-NETs up to a Ki-67 of 10% [I,
A; ESMO-MCBS v1.1 score: 3] for lanreotide and [I, A;
ESMO-MCBS v1.1 score: 2] for octreotide. Positive SSTR
status is generally required but is not predictive of
response.
 IFN-a can be considered for antiproliferative therapy
if other treatment options have been exploited or
are not feasible (e.g. SSTR-negative on functional
imaging), particularly in midgut NETs, where there
are fewer therapy options compared with Pan-NETs
[IV, B].
 Everolimus is EMA-approved for progressive Pan-NET G1/
G2 with or without prior ChT, for NF-GI and lung NETs [I, A;
ESMO-MCBS v1.1 score: 3]. In GI NETs, everolimus should
be used in patients with clearly progressive disease [I, A].
 The use of everolimus after PRRT is recommended in
intestinal NETs, if PRRT is available [V, A], although the
treatment sequence needs to be further studied in the
absence of definite predictors of response.
 The combination therapy of SSA and everolimus for an
antiproliferative purpose is not recommended [II, D].Volume xxx - Issue xxx - 2020
M. Pavel et al. Annals of Oncology Sunitinib is one of the EMA-approved treatment options
in advanced progressive Pan-NETs [I, A; ESMO-MCBS v1.1
score: 3].
 Both sunitinib and everolimus cannot be recommended
in NEC G3 outside of clinical trials [V, E].
 The use of systemic ChT is recommended in advanced
Pan-NETs and in NEN G3 of any site [II, A].
B In patients with non-resectable LMs and/or other
distant metastases from G1/G2 Pan-NETs, STZ/5-FU is
recommended in progressive disease [II, A].
B TEM alone or in combination with CAP is recommen-
ded as alternative ChT in Pan-NETs [II, B].
B Systemic ChT can also be recommended in bulky
disease without prior tumour progression in
Pan-NETs [II, B].
B Cisplatin or carboplatin with etoposide is recommen-
ded standard first-line ChT in NEC G3 [III, A]. There is
no established second-line therapy, but different
regimens [e.g. 5-FU/leucovorin/irinotecan (FOLFIRI),
5-FU/leucovorin/oxaliplatin (FOLFOX), CAPTEM 
bevacizumab] may be considered [IV, B].
 In NET G3, response rates to cisplatin/etoposide are
low, and the use of this combination is not recommen-
ded [IV, C].
 ChT cannot be recommended in well-differentiated
slowly growing NETs of the GI tract [II, C]; exceptions
may be rapidly progressive tumours or NET G2 with
higher Ki-67 close to NET G3 [V, C].
 PRRT is recommended as second-line therapy in patients
with midgut NETs with disease progression on SSAs who
fulfil the general requirements for PRRT [I, A].
 177Lu-DOTATATE is EMA- and FDA-approved for patients
with midgut NETs [I, A; ESMO-MCBS v1.1 score: 4] and
Pan-NETs [III, A; ESMO-MCBS v1.1 score: 4].
 In Pan-NETs, PRRT should be used after failure of
approved therapies [III, A].
 In carefully selected patients, PRRT may be considered in
NET G3 [IV, C].
 SSA should be combined with PRRT in patients with
functioning tumours (CS) to prevent increasing symp-
toms such as diarrhoea and/or flushing and hormonal
crisis soon after PRRT [II, A].
 It is also common practice to continue SSA beyond PRRT
in functioning tumours, as a full resolution of CS-related
symptoms is rarely achieved after PRRT [II, A].
 The combination of SSA with PRRT is not recommended
in patients with NF-NETs, [IV, C] and it remains unclear if
SSA should be continued after PRRT as a maintenance
therapy.
PERSONALISED MEDICINE
In the absence of definite predictive markers and paucity of
comparative randomised trials, therapy selection in
advanced non-resectable disease is frequently based on
individual patient clinical and pathological features and
SSTR imaging [IV, A]. Several issues are unresolved: to
consider surgery upfront for potentially resectable LMs or
systemic therapy, or locoregional therapies. AmongVolume xxx - Issue xxx - 2020systemic treatments, approved drugs should be used with
higher priority, although comorbidities and age may impact
treatment choices. The treatment selection should be based
on an interdisciplinary tumour board decision in experi-
enced centres including experts familiar with the disease.
Recently identified prognostic molecular markers may have
an impact on therapy strategies in the future if validated in
prospective trials. A recent meta-analysis identified a diag-
nostic accuracy of a NET mRNA genomic biomarker (NETest)
of 95%e96%; this marker seems to have a predictive value
for PRRT response and achievement of complete surgery.103
Recommendation In the absence of definite predictive markers and paucity
of comparative randomised trials, therapy selection in
advanced disease is often based on individual patient clin-
ical and pathological features and SSTR imaging [IV, A].FOLLOW-UP, LONG-TERM IMPLICATION AND
SURVIVORSHIP
Follow-up investigations should include clinical symptom
monitoring, biochemical parameters and conventional and
SSTR imaging [V, B]. In patients with R0/R1-resected NET G1
and NET G2 with low Ki-67 (<5%), it is recommended that
imaging is carried out every 6 months (CT or MRI), in NET
G2 (Ki-67 >5%) every 3 months and in NEC G3 every 2e3
months [V, C]. Similar staging intervals apply to advanced
disease. Follow-up should be life long, although the staging
intervals can be extended to 1e2 years with increasing
length of follow-up (>5 years), except in G3 NEN, where
shorter intervals should be kept. Late recurrences after 10e
20 years have been described, although rare. In contrast,
small localised NET G1 (<1 cm in size) with origin in the
appendix or rectum do not need any follow-up if
R0-resected and in the absence of adverse histological
features [IV, A].
Imaging with 68Ga/64Cu-SSTR-PET-CT, or if not available
with SSTR scintigraphy as a considerably less sensitive
alternative, should be included in the follow-up and is
recommended after 12e36 months if expression of SSTR-2a
has been demonstrated on the tumour cells by previous
SSTR imaging or IHC.91,92 In the follow-up, a re-biopsy of the
liver or other disease site (in absence of LMs) may be
considered under special circumstances, e.g. if a second
malignancy is suspected or the tumour growth behaviour is
inconsistent with the known Ki-67 and warrants exclusion of
a NEC. Biochemical markers include CgA and specific bio-
markers in functional tumours; if CgA is not elevated, NSE
represents an alternative biomarker, mostly in NET G2 or
NEN G3. There is no validated tumour marker for recurrence
detection; the NETest has potential to predict response to
PRRT and detect residual disease after surgery and was
superior to CgA in a validation study.104e106
In NEN G3 clinical symptoms (weight loss, fatigue; also
indicative in G1 and G2) may indicate recurrence. NSE and
lactate dehydrogenase (LDH) should be monitored in NEC;https://doi.org/10.1016/j.annonc.2020.03.304 13
Annals of Oncology M. Pavel et al.CgA may also be elevated in NET G3. Conventional imaging
includes thoracic and abdominal scans every 2e3 months.
FDG-PETmay be required in case of suspected recurrence to
discriminate lesions from unspecific findings; otherwise,
high-resolution CT is the imaging method of choice, unless
resection is considered in locally advanced NEN G3,
where FDG-PET is mandatory to exclude distant metastatic
disease.
Recommendations Follow-up investigations should include clinical symptom
monitoring, biochemical parameters and conventional
and SSTR imaging [V, B].
 In patients with R0/R1-resected NET G1eG2, it is recom-
mended that imaging is carried out every 3e6 months
(CT or MRI), and in NEC G3 every 2e3 months [V, C].
Similar staging intervals apply to advanced disease.
 Follow-up should be lifelong, although the staging inter-
vals may be extended to 1e2 years with increasing
length of follow-up.
 Small localised NET G1 (<1 cm in size) with origin in the
appendix or rectum do not need any follow-up if
R0-resected and in the absence of adverse histological
features [IV, A].
METHODOLOGY
These Clinical Practice Guidelines were developed in
accordance with the ESMO standard operating procedures
for Clinical Practice Guidelines development, http://www.
esmo.org/Guidelines/ESMOGuidelines-Methodology. The
relevant literature has been selected by the expert authors.
An ESMO-MCBS table with ESMO-MCBS scores is included
in supplementary Table S4, available at Annals of Oncology
online.107 Levels of evidence and grades of recommenda-
tion have been applied using the system shown in
supplementary Table S5, available at Annals of Oncology
online.108 Statements without grading were considered
justified standard clinical practice by the experts and the
ESMO Faculty. This manuscript has been subjected to an
anonymous peer review process.
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